|
US7646707B2
(en)
*
|
2003-12-23 |
2010-01-12 |
At&T Intellectual Property I, L.P. |
Method and system for automatically renaming logical circuit identifiers for rerouted logical circuits in a data network
|
|
MXPA06008095A
(es)
*
|
2004-01-16 |
2007-03-28 |
Univ Michigan |
Mimeticos de smac conformacionalmente restringidos y sus usos.
|
|
CA2553871A1
(en)
*
|
2004-01-16 |
2005-08-04 |
The Regents Of The University Of Michigan |
Smac peptidomimetics and the uses thereof
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
CA2570321C
(en)
*
|
2004-07-02 |
2013-10-08 |
Genentech, Inc. |
Inhibitors of iap
|
|
WO2006010118A2
(en)
*
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
|
BRPI0513310A
(pt)
*
|
2004-07-12 |
2008-05-06 |
Idun Pharmaceuticals Inc |
análogos de tetrapeptìdeo
|
|
WO2006020060A2
(en)
|
2004-07-15 |
2006-02-23 |
Tetralogic Pharmaceuticals Corporation |
Iap binding compounds
|
|
KR20120127754A
(ko)
|
2004-12-20 |
2012-11-23 |
제넨테크, 인크. |
Ｉａｐ의 피롤리딘 억제제
|
|
DK1851200T3
(da)
|
2005-02-25 |
2014-04-14 |
Tetralogic Pharm Corp |
Dimere iap-inhibitorer
|
|
JP4954983B2
(ja)
|
2005-05-18 |
2012-06-20 |
ファーマサイエンス・インコーポレイテッド |
Ｂｉｒドメイン結合化合物
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
JP2009509128A
(ja)
*
|
2005-08-09 |
2009-03-05 |
テトラロジック ファーマシューティカルズ コーポレーション |
増殖性疾患の治療
|
|
RU2418807C2
(ru)
*
|
2005-10-25 |
2011-05-20 |
Аегера Терапьютикс Инк. |
Соединения, связывающие bir домены iap
|
|
RU2451025C2
(ru)
*
|
2005-12-19 |
2012-05-20 |
Дженентек, Инк. |
Ингибиторы iap
|
|
TWI543988B
(zh)
|
2006-03-16 |
2016-08-01 |
科學製藥股份有限公司 |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
SG10201407457UA
(en)
*
|
2006-05-16 |
2014-12-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014238A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
JP5452223B2
(ja)
*
|
2006-07-24 |
2014-03-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
Ｉａｐ阻害剤
|
|
CL2007002167A1
(es)
*
|
2006-07-24 |
2009-01-23 |
Tetralogic Pharm Corp |
Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
|
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20110218A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
RU2009110254A
(ru)
*
|
2006-08-24 |
2010-09-27 |
Новартис АГ (CH) |
Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений
|
|
CN101516877B
(zh)
*
|
2006-09-22 |
2013-09-11 |
诺瓦提斯公司 |
杂环有机化合物
|
|
US8044209B2
(en)
|
2006-10-12 |
2011-10-25 |
Novartis Ag |
Pyrrolydine derivatives as IAP inhibitors
|
|
RU2466131C2
(ru)
*
|
2006-12-19 |
2012-11-10 |
Дженентек, Инк. |
Имидазопиридиновые ингибиторы iap
|
|
EP2121671A1
(en)
*
|
2006-12-20 |
2009-11-25 |
Novartis AG |
2-substituted 5-membered heterocycles as scd inhibitors
|
|
WO2008128121A1
(en)
*
|
2007-04-12 |
2008-10-23 |
Joyant Pharmaceuticals, Inc. |
Smac mimetic dimers and trimers useful as anti-cancer agents
|
|
NZ598890A
(en)
*
|
2007-04-30 |
2013-10-25 |
Genentech Inc |
Inhibitors of iap
|
|
CA2686638A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Tetralogic Pharmaceuticals Corp. |
Tnf.alpha. gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
|
|
WO2008144925A1
(en)
*
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
PL2240506T3
(pl)
*
|
2008-01-11 |
2013-05-31 |
Genentech Inc |
Inhibitory IAP
|
|
WO2009136290A1
(en)
*
|
2008-05-05 |
2009-11-12 |
Aegera Therapeutics, Inc. |
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
AU2009261919A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Pharmascience Inc. |
Bridged secondary amines and use thereof as IAP BIR domain binding compounds
|
|
CA2730448A1
(en)
*
|
2008-08-02 |
2010-02-11 |
Genentech, Inc. |
Inhibitors of iap
|
|
JP2012500272A
(ja)
*
|
2008-08-16 |
2012-01-05 |
ジェネンテック， インコーポレイテッド |
Ｉａｐのアザインドールインヒビター
|
|
AU2009293403A1
(en)
|
2008-09-17 |
2010-03-25 |
Tetralogic Pharmaceuticals Corp. |
IAP inhibitors
|
|
FR2939073B1
(fr)
|
2008-12-03 |
2010-12-31 |
Sidel Participations |
Formage des recipients avec contre-pression localisee
|
|
US20100317593A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
WO2011035083A1
(en)
|
2009-09-18 |
2011-03-24 |
Novartis Ag |
Biomarkers for iap inhibitor compounds
|
|
CA2789879A1
(en)
|
2009-10-28 |
2011-05-19 |
Joyant Pharmaceuticals, Inc. |
Dimeric smac mimetics
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
MX340870B
(es)
|
2010-02-12 |
2016-07-27 |
Pharmascience Inc |
Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
|
|
WO2011128304A2
(de)
|
2010-04-16 |
2011-10-20 |
Bayer Cropscience Ag |
Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
|
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
WO2013043591A1
(en)
*
|
2011-09-21 |
2013-03-28 |
Albert Einstein College Of Medicine Of Yeshiva University |
Combination therapy for cancer
|
|
EP2760446A1
(en)
|
2011-09-30 |
2014-08-06 |
Tetralogic Pharmaceuticals Corporation |
Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
|
|
NO2755614T3
(enExample)
*
|
2012-01-03 |
2018-03-31 |
|
|
|
BR112014027413A2
(pt)
|
2012-05-04 |
2017-06-27 |
Novartis Ag |
biomarcadores para terapia com inibidor de iap
|
|
CA2896577C
(en)
|
2012-11-30 |
2024-01-23 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (iap) antagonists
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
BR112015021134A2
(pt)
|
2013-03-15 |
2017-10-10 |
Novartis Ag |
conjugados de fármaco e anticorpo
|
|
MX381320B
(es)
|
2013-06-25 |
2025-03-12 |
Walter & Eliza Hall Inst Medical Res |
Usos de antagonistas de iap en infecciones intracelulares.
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
WO2015092420A1
(en)
|
2013-12-20 |
2015-06-25 |
Astex Therapeutics Limited |
Bicyclic heterocycle compounds and their uses in therapy
|
|
US10441654B2
(en)
|
2014-01-24 |
2019-10-15 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
SMC combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2015168835A1
(en)
*
|
2014-05-05 |
2015-11-12 |
Empire Technology Development Llc |
Composite task processor
|
|
EP3151920B1
(en)
|
2014-06-04 |
2025-08-06 |
Sanford-Burnham Medical Research Institute |
Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
PE20170903A1
(es)
|
2014-08-12 |
2017-07-12 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6
|
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
HK1245791A1
(zh)
|
2015-01-20 |
2018-08-31 |
阿尔维纳斯运营股份有限公司 |
用於雄激素受体的靶向降解的化合物和方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
SG11201802769RA
(en)
|
2015-10-29 |
2018-05-30 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
EP4257191A3
(en)
|
2016-06-21 |
2023-11-22 |
Orion Ophthalmology LLC |
Heterocyclic prolinamide derivatives
|
|
WO2017222914A1
(en)
|
2016-06-21 |
2017-12-28 |
Inception 4, Inc. |
Carbocyclic prolinamide derivatives
|
|
EP3535265A4
(en)
|
2016-11-01 |
2020-07-08 |
Arvinas, Inc. |
PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
|
|
WO2018102725A1
(en)
|
2016-12-01 |
2018-06-07 |
Arvinas, Inc. |
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
|
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
|
|
EP3558994A4
(en)
|
2016-12-23 |
2021-05-12 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
RU2019121527A
(ru)
|
2016-12-23 |
2021-01-15 |
Эрвинэс Оперейшнс, Инк. |
Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
MX2019008934A
(es)
|
2017-01-26 |
2019-11-05 |
Arvinas Operations Inc |
Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
EP3592868B1
(en)
|
2017-03-06 |
2022-11-23 |
Novartis AG |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
CN110662762A
(zh)
|
2017-05-24 |
2020-01-07 |
诺华股份有限公司 |
抗体细胞因子移植蛋白和用于治疗癌症的方法
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
JP2020520671A
(ja)
|
2017-05-24 |
2020-07-16 |
ノバルティス アーゲー |
抗体−サイトカイングラフト化タンパク質及び使用方法
|
|
IL274598B2
(en)
|
2017-11-13 |
2025-01-01 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
SMAC mimetics used as IAP inhibitors and their use
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
JP7161849B2
(ja)
*
|
2018-01-24 |
2022-10-27 |
株式会社クラレ |
第一級アミンの製造方法
|
|
WO2019154053A1
(zh)
*
|
2018-02-09 |
2019-08-15 |
广东东阳光药业有限公司 |
Iap抑制剂及其在药物中的应用
|
|
CN119569702A
(zh)
|
2018-04-04 |
2025-03-07 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
|
CU20210002A7
(es)
|
2018-07-10 |
2021-08-06 |
Novartis Ag |
Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
IL319737A
(en)
|
2018-09-07 |
2025-05-01 |
Arvinas Operations Inc |
Polycyclic compounds and methods for targeted reduction of rapidly accelerating fibrosarcoma polypeptides
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
PH12021551479A1
(en)
|
2018-12-21 |
2022-07-18 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2020177765A1
(zh)
*
|
2019-03-07 |
2020-09-10 |
正大天晴药业集团股份有限公司 |
Iap抑制剂与免疫检查点抑制剂的组合
|
|
JP7587526B2
(ja)
*
|
2019-05-10 |
2024-11-20 |
チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド |
Ｉａｐ阻害剤としてのｓｍａｃ模倣物の結晶及びその製造方法
|
|
WO2021011913A1
(en)
|
2019-07-17 |
2021-01-21 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
WO2021023698A1
(en)
|
2019-08-02 |
2021-02-11 |
Lanthiopep B.V |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
ES3061133T3
(en)
|
2019-08-26 |
2026-03-31 |
Arvinas Operations Inc |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
|
EP4093394A1
(en)
|
2020-01-20 |
2022-11-30 |
Astrazeneca AB |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
CN111205232B
(zh)
*
|
2020-02-26 |
2022-07-01 |
浙江天宇药业股份有限公司 |
一种替格瑞洛中间体的合成方法
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP4204418A1
(en)
|
2020-08-28 |
2023-07-05 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024023666A1
(en)
|
2022-07-26 |
2024-02-01 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|